Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Moderna $3 billion convertible notes offering and capped call transactions
We advised the initial purchasers on the offering
Jazz Pharmaceuticals $1.25 billion exchangeable senior notes offering
We advised the initial purchasers on the offering
Immatics $172.5 million follow-on offering
We advised Immatics on the offering
McKesson $2.25 billion acquisition of Precision Medicine Group
We are advising McKesson on the transaction
Aveanna $203 million secondary offering
We advised the underwriters on the offering
Oruka Therapeutics $500 million at-the-market offering
We advised Oruka on the offering
AbbVie $10 billion senior notes offering
We advised the underwriters on the offering
Illumina $300 million notes offering
We advised the underwriters on the offering
PetIQ acquisition of MYOS
We advised Bansk Group and its portfolio company PetIQ on the transaction
Integer Holdings $5.7 billion sale to KKR
We are advising Integer on the transaction